Entasis Therapeutics to Report Second Quarter 2021 Results and Host Conference Call August 12, 2021
Entasis Therapeutics Holdings (NASDAQ: ETTX) will announce its Q2 2021 financial results on August 12, 2021, before market opening. A conference call is scheduled at 8:00 AM ET to discuss the results, including a clinical and corporate update, followed by a Q&A session. Investors can join the call via phone or through a live audio webcast. Entasis specializes in developing novel antibacterial products targeting multidrug-resistant Gram-negative infections, with candidates like sulbactam-durlobactam and zoliflodacin.
- None.
- None.
WALTHAM, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that management will report second quarter 2021 financial results before the market opens on August 12, 2021. The company will host a conference call and webcast at 8:00AM Eastern Time to discuss its results and provide a clinical and corporate update. A question-and-answer session will follow management’s prepared remarks.
Investors and the general public are invited to listen to a live audio webcast of the conference call, which may be accessed five minutes prior to the start of the call by dialing 877-407-4018 (U.S.) or 201-689-8471 (international) or through the link http://public.viavid.com/index.php?id=145976. A replay of the call will be available from the Entasis website at www.entasistx.com following the call.
About Entasis
Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis’ pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae infections), ETX0282CPDP (targeting Enterobacteriaceae infections) and ETX0462 (targeting Pseudomonas infections). For more information, visit www.entasistx.com.
Company Contact:
Kyle Dow
Entasis Therapeutics
(781) 810-0114
kyle.dow@entasistx.com
Investor Relations Contact:
Bruce Mackle
LifeSci Advisors
(929) 469-3859
bmackle@lifesciadvisors.com
FAQ
When will Entasis Therapeutics report its Q2 2021 financial results?
What time is the conference call for Entasis Therapeutics Q2 2021 results?
How can I listen to the Entasis Therapeutics conference call?
What is the focus of Entasis Therapeutics?
What notable products are in Entasis Therapeutics' pipeline?
